

Controlled Substances

Product	Indication	Regulatory Documentation
Amfepramon Hydrochloride	Appetite depressant	US-DMF, ASMF
Buprenorphine	Analgesic	CEP, US-DMF, ASMF
Buprenorphine Hydrochloride	Analgesic	CEP, US-DMF, ASMF
Fentanyl	Analgesic	CEP, ASMF
Fentanyl Citrate	Analgesic	CEP, ASMF
Remifentanil Hydrochloride	Analgesic	CEP, ASMF
Tilidine Hydrochloride Hemihydrate	Analgesic	CEP, ASMF

Portfolio APIs

Product	Indication	Regulatory Documentation
Amiodarone Hydrochloride	Antiarrhythmic	CEP, ASMF
Bisoprolol Fumarate	Antihypertonic, beta block	CEP, US-DMF, J-DMF, ASMF
Cafedrine Hydrochloride	Cardiac Stimulant	ASMF
Cannabidiol	Anti-epileptic, Various	ASMF
Carbamazepine	Antiepileptic, Anticonvulsant	CEP, ASMF
Cetirizine Dihydrochloride	Antihistaminic	CEP, ASMF
Dimethylfumarate	Psoriasis, Multiple Sclerosis	US-DMF, ASMF
Doxapram Hydrochloride	Analeptic	CEP, US-DMF, J-DMF
Ebastine	Antihistaminic	CEP, ASMF
Esketamine Hydrochloride	Analgesic, Anti-depressant	CEP, US-DMF, ASMF
Ketamine Hydrochloride	Analgesic	CEP, US-DMF, ASMF
Phenprocoumon	Anticoagulant	ASMF
Phytosterol	Urological diseases	ASMF
Pyridostigmine Bromide	Parasympathomimetic	CEP, C-DMF, ASMF
Sultiame	Antiepileptic, Anticonvulsant	ASMF
Theodrenaline	Cardiac Stimulant	ASMF
Torsemide	Diuretic	CEP, ASMF, J-DMF

R&D Products

Product	Indication	Status
Alpelisib	Anticancer	Under Evaluation
Arketamine HCl	Antidepressant	Validation Completed
Cocaine	Analgesic	Under Evaluation
Diroximel Fumarate	Multiple Sclerosis	Under Evaluation
Gilteritinib	Anticancer	Under Evaluation
(Hydroxy-/) Norketamine	Antidepressant	Laboratory Assessment
LSD (Lysergic acid diethylamide)	Antidepressant, Addiction	Under Evaluation
MDMA (Methylene dioxymethamphetamine)	PTSD	Under Evaluation
Oliceridine	Analgesic	Under Evaluation
Ribociclib	Anticancer	Under Evaluation
Rivastigmine (Tartrate)	Alzheimer	Validation Q2 2024
Sufentanil	Analgesic	Laboratory Assessment
Tirbanibulin	Actinic keratosis	Under Evaluation